Anteris Technologies Global Corp. (AVR)

NASDAQ: AVR · Real-Time Price · USD
6.51
+0.17 (2.68%)
At close: Feb 27, 2026, 4:00 PM EST
6.59
+0.08 (1.22%)
After-hours: Feb 27, 2026, 7:55 PM EST
2.68%
Market Cap 609.56M
Revenue (ttm) 1.91M
Net Income (ttm) -94.14M
Shares Out 97.23M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,055,986
Open 6.20
Previous Close 6.34
Day's Range 6.20 - 6.84
52-Week Range 2.34 - 8.36
Beta 0.41
Analysts n/a
Price Target n/a
Earnings Date Feb 26, 2026

About AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s... [Read more]

Sector Healthcare
IPO Date Dec 13, 2024
Employees 136
Stock Exchange NASDAQ
Ticker Symbol AVR
Full Company Profile

Financial Performance

In 2025, AVR's revenue was $1.91 million, a decrease of -29.23% compared to the previous year's $2.70 million. Losses were -$94.14 million, 23.4% more than in 2024.

Financial Statements

News

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...

5 weeks ago - GlobeNewsWire

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...

5 weeks ago - GlobeNewsWire

Anteris Technologies Surges On Pricing Of $200Mln Public Offering

(RTTNews) - Shares of Anteris Technologies Global Corp (AVR, AVR.AX) are up over 18% at $6.82 in premarket trading on Wednesday, following the pricing of its public offering.

5 weeks ago - Nasdaq

What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours?

Anteris Technologies Global Corp. (NASDAQ: AVR) shares jumped 52.17% in after-hours trading on Tuesday, reaching $8.75, following the announcement of a major capital raise. According to Benzinga Pro ...

5 weeks ago - Benzinga

Anteris Prices $200 Mln Public Offering; Announces Medtronic Private Placement Up To $90 Mln

(RTTNews) - Anteris Technologies Global Corp. (AVR, AVR.AX), a medical technology company, on Tuesday, priced its public offering of 34.78 million shares at $5.75 per share, raising expected gross pro...

5 weeks ago - Nasdaq

Anteris Technologies Global prices $200M public offering and concurrent $90M Medtronic placement

Anteris Technologies Global (AVR) announced the pricing of its public offering of 34,782,609 shares at $5.75 per share, to raise about $200 million from this offering, before deductions. The offering ...

5 weeks ago - Seeking Alpha

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...

5 weeks ago - GlobeNewsWire

Anteris Technologies (AVR) Reports Promising Results for DurAVR THV in Aortic Stenosis

Anteris Technologies (AVR) Reports Promising Results for DurAVR THV in Aortic Stenosis

3 months ago - GuruFocus

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for th...

3 months ago - GlobeNewsWire

Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp

Sio Capital Management, LLC Reduces Stake in Anteris Technologies Global Corp

3 months ago - GuruFocus

Anteris Announces Results for the Third Quarter of 2025

MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company comm...

3 months ago - GlobeNewsWire

Anteris Technologies (AVR) Reports Promising One-Year Results for DurAVR Heart Valve

Anteris Technologies (AVR) Reports Promising One-Year Results for DurAVR Heart Valve

4 months ago - GuruFocus

Anteris Technologies (AVR) Advances DurAVR Heart Valve Trial

Anteris Technologies (AVR) Advances DurAVR Heart Valve Trial

4 months ago - GuruFocus

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa...

4 months ago - GlobeNewsWire

Anteris Technologies (AVR) to Present Key Clinical Outcomes at TCT 2025

Anteris Technologies (AVR) to Present Key Clinical Outcomes at TCT 2025

4 months ago - GuruFocus

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed t...

4 months ago - GlobeNewsWire

L1-backed heart medtech Anteris Technologies rakes in $39m

The placement, launched on Friday, was originally pegged at $30 million but was upsized following excess demand.

4 months ago - The Australian Financial Review

Anteris Technologies (AVR) Gains Approval for Global Heart Valve Trial in Denmark

Anteris Technologies (AVR) Gains Approval for Global Heart Valve Trial in Denmark

4 months ago - GuruFocus

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...

5 months ago - GlobeNewsWire

Anteris Technologies (AVR) Reschedules Special Stockholders Meeting

Anteris Technologies (AVR) Reschedules Special Stockholders Meeting

6 months ago - GuruFocus

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...

6 months ago - GlobeNewsWire

Anteris Technologies reports Q2 results

7 months ago - Seeking Alpha

Anteris Announces Results for the Second Quarter of 2025

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...

7 months ago - GlobeNewsWire

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...

9 months ago - GlobeNewsWire